Investor Presentation
|
|
- Gervase Hill
- 5 years ago
- Views:
Transcription
1 Investor Presentation September GW Pharmaceuticals plc All Rights Reserved
2 Disclaimers FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management s beliefs and assumptions and on information currently available to management. Forward-looking statements include information about our current expectations for future events, including potential results of operations, the timing of clinical trials, the timing of regulatory filings, the timing and outcomes of regulatory or intellectual property decisions, demand for our commercially available products and products in development and the clinical benefits, safety profile and commercial potential of Sativex and Epidiolex. These forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause our actual results, performance or achievements to be materially different than any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our management s beliefs and assumptions only as of the date of this presentation. You should read our most recent Annual Report, as filed on Form 20-F with the Securities and Exchange Commission, including the Risk Factors set forth therein and the exhibits thereto, and our subsequent filings with the Securities and Exchange Commission, completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. GW Pharmaceuticals plc Investor Presentation 1
3 GW S VISION is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs GW Pharmaceuticals plc Investor Presentation 2
4 Greenwich Biosciences & GW Pharmaceuticals RESEARCH DEVELOPMENT COMMERCIALIZATION 20+ years experience in researching and developing novel Rx cannabinoid medicines >500 person in-house team with expertise in bringing drugs to regulatory approval in US and ROW 14 cannabinoids evaluated in pre-clinical research >80 peer-reviewed publications Cannabinoids exported to >35 countries for research >50 Phase 2/3 clinical trials >55,000 patient-years of human safety data Sativex approved in >25 countries (ex- US) for relief of MS spasticity The World Leader in Cannabinoid Science Epidiolex Approved by FDA MAA application accepted for review US commercial launch expected in Fall 2018, pending rescheduling EU commercial infrastructure build ongoing Increased scale commercial manufacturing in place for Epidiolex launch Connect Most Innovative New Product Award Submission for Epidiolex (cannabidiol) oral solution 3
5 Epidiolex (cannabidiol) oral solution Treatment-Resistant Epilepsy Overview Extensive CBD pre-clinical research since 2007 showing in vivo and in vitro efficacy Positive data from three Phase 3 placebo-controlled trials in initial target orphan indications of Dravet syndrome and Lennox-Gastaut syndrome (LGS) Publication of Dravet and LGS Phase 3 trial results in The New England Journal of Medicine and first LGS Phase 3 results in The Lancet Epidiolex approved by FDA on June 25, 2018, pending rescheduling, commercial launch expected in the Fall, 2018 EMA submission accepted for review, expected decision in Q Novel mechanism of action in epilepsy - CBD does not act through cannabinoid (CB) receptors or sodium channels - Prime targets are GPR55 and adenosine reuptake, TRPV1 Significant patient and physician interest with over 2,000 patients now treated with Epidiolex Real-world experience in Epidiolex use - Data from >1,000 patients in compassionate use program show treatment effect and safety across a range of severe epilepsy types Active lifecycle management plan, including additional target orphan indications Epidiolex (cannabidiol) is an investigational product outside of the United States of America Connect Most Innovative New Product Award Submission for Epidiolex (cannabidiol) oral solution 4
6 Significant Unmet Need in Epilepsy 2.2 million US patients with epilepsy (~470,000 children) - ~ One third of patients are pharmacoresistant with seizures persisting despite multiple antiepileptic drugs (AEDs) Childhood-onset epilepsy - Multiple distinct orphan syndromes, almost none with a specific indicated therapy - Many syndromes highly resistant to currently available AEDs - Seizures continue into adulthood Dravet syndrome and LGS represent two of the most difficult-to-treat epilepsy syndromes - Multiple seizure types, developmental delay, high risk of SUDEP - Highly refractory even with current medications, polytherapy generally required Physicians seek new treatment options - Majority of physicians not satisfied with current therapeutic options Sources: Sander JW, Epilepsia. 1993;34(6):1007; Picot et al, 2008 ; Kwan P, Brodie MJ. N Engl J Med. 2000;342: ; Kwan P, Brodie MJ, CNS Spectr. 2004;9(2):110 3 Picot et al, 2008; Kwan P, Brodie MJ. N Engl J Med. 2000;342: ; Kwan P, Brodie MJ, CNS Spectr. 2004;9(2):110, Morgan Stanley research (2015) GW Pharmaceuticals plc Investor Presentation 5
7 The Epidiolex Story: A History of Milestone Achievements Q4 12 First child treated with Epidiolex Q2 14 FDA grants GW IND Formal GW CBD development program begins Q Phase 3 studies in Dravet and LGS started and enrolled Q LGS 1 topline results TSC Phase 3 trial started Q AES: Dravet 1 LGS 1 Q Dravet trial results published in NEJM Dec 2017 Epidiolex MAA submission Feb 2017 Epidiolex MAA accepted for review June 25, 2018 Epidiolex approved by the FDA #1 Q1 14 EAPs (Expanded Access Programs) initiated Q4 14 Dravet 1 Part A started Q Dravet 1 topline results Q LGS 2 topline results Q AAN: LGS 2 Oct 2017 Epidiolex NDA for Dravet and LGS Dec 2017 NDA accepted for review: mid-2018 PDUFA Jan 2018 LGS trial results published in The Lancet Q nd LGS trial results published in NEJM 2,000 patients have been treated with Epidiolex Connect Most Innovative New Product Award Submission for Epidiolex (cannabidiol) oral solution 6
8 Epidiolex Expanded Access Program FDA authorized, physician-sponsored expanded access program (EAP) initiated in early Children and young adults with multiple etiologies, all with treatment-resistant epilepsy - ~20 physician site EAPs and 6 US state sponsored EAP programs - Over 1,100 patients approved for treatment by FDA Most recent EAP data presented in abstracts at AES Long-term (96-week) Epidiolex safety and treatment effect data - All Children and Adults with Treatment-Resistant Epilepsies (Bebin et al, 2017) - Patients with LGS & Dravet syndrome (Laux et al, 2017) - For both convulsive and total seizures, median % reductions and 50%, 75% and 100% responder rates were consistent across all time points - CBD was generally well tolerated, adverse events (AEs) were consistent with those seen in previous pivotal and expanded access reports AES 2017 EAP Median % Reduction in Seizures All Patients with TRE Convulsive Seizures Total Seizures Patients with LGS and Dravet Syndrome Only Convulsive Seizures Total Seizures GW Pharmaceuticals plc Investor Presentation 7
9 Epidiolex Clinical Program
10 Physician Sponsored GW Sponsored Solution: Epidiolex Clinical Program Overview Dravet Syndrome Phase 3 (n=120) Positive Phase 3 (n=186) Fully Recruited FDA approval on June 25 th, 2018 Lennox-Gastaut Syndrome Tuberous Sclerosis Complex Phase 3 (n=171) Positive Phase 3 (n=225) Positive NDA MAA Phase 3 (n=210) Recruiting FDA Approval MAA submission accepted Feb 18 with expected decision in Q Childhood Epilepsy Syndromes Ongoing Treatment Data from >1,000 patients Other Epilepsies Greenwich makes Epidiolex available to the most needy patients through an innovative compassionate use program Connect Most Innovative New Product Award Submission for Epidiolex (cannabidiol) oral solution 9
11 Median % Reduction Median % Reduction Phase 3 Dravet 1 Syndrome Trial Principal Efficacy Results p= Convulsive Seizures p= p= Total Seizures p= Treatment Period Maintenance Period 0 Treatment Period Maintenance Period 20 mg/kg/day CBD (n=61) Placebo (n=59) Source: J. H. Cross, O. Devinsky, L. Laux, E. Marsh, I. Miller, R. Nabbout, I. Scheffer, E. Thiele, S. Wright, Cannabidiol (CBD) reduces convulsive seizure frequency in Dravet Syndrome: results of a multi-centered, randomized, controlled study, Abstract No 2.362, 2016, American Epilepsy Society Annual Meeting GW Pharmaceuticals plc Investor Presentation 10
12 Median % Reduction Median % Reduction Phase 3 LGS 1 (Single Dose Cohort) Trial Principal Efficacy Results p= Drop Seizures p= p= Total Seizures p= Treatment Period Maintenance Period 0 Treatment Period Maintenance Period 20 mg/kg/day CBD (n=86) Placebo (n=85) Source: E. Thiele, M. Mazurkiewicz-Beldzinska, S. Benbadis, E. Marsh, C. Joshi, J. French, C. Roberts, A. Taylor, K. Sommerville, Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut syndrome: results of a multicenter, randomized, double blind, placebo-controlled trial, Abstract No 1.377, 2016, American Epilepsy Society Annual Meeting GW Pharmaceuticals plc Investor Presentation 11
13 Median % reduction / 28 days % Patients Phase 3 LGS 2 (Multiple Dose Cohorts) Trial Principal Efficacy Results Reduction in Drop Seizures Treatment Period (Primary) Maintenance Period p< * 62 Drop Seizure Responder Rates Treatment Period * GW Pharmaceuticals plc Investor Presentation % 50% 75% CBD 20 mg/kg/day (n=76) CBD 10 mg/kg/day (n=73) Placebo (n=76) 5 CBD 20 mg/kg, 3 CBD 10 mg/kg, and 1 placebo patient achieved drop seizure freedom during maintenance Cannabidiol (CBD) Significantly Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome (LGS): Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial (GWPCARE3) A.D. Patel, O. Devinsky, J.H. Cross, V. Villanueva, E. Wirrell, K. VanLandingham, C. Roberts, D. Checketts, S. Zuberi, American Academy of Neurology Annual Meeting * 11 * p<0.05 p<0.01 p<
14 Phase 3 Safety Profile Consistent adverse reaction profile across pivotal trials. Most common AEs (>10% of patients) in Phase 3 trials include: - somnolence; decreased appetite; diarrhea; transaminase elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder and poor-quality sleep, and infections. - Warnings & Precautions related to hepatocellular injury and somnolence & sedation are included in the US Prescribing Information Low withdrawal rates seen throughout clinical program Elevations in hepatic transaminases have been reported, most commonly with concomitant valproate; none met criteria for serious liver injury; all elevations resolved most while on treatment - Physicians routinely monitor liver function in patients with epilepsy as there are a number of approved AEDs that are associated with elevations in transaminases - Monitoring recommendations and lower starting dose are included in US PI to help physicians manage potential liver risks Across the Phase 3 program, Epidiolex was generally welltolerated, with most AEs reported as mild or moderate GW Pharmaceuticals plc Investor Presentation 13
15 3rd Target Indication: Tuberous Sclerosis Complex (TSC) Selection of these indications driven by encouraging EAP data Tuberous Sclerosis Complex (~25,000 US TSC patients with treatment resistant seizures) - Single Phase 3 pivotal trial underway - TSC is a genetic disorder that results from a mutation in tumor suppressor genes genes TSC1 or TSC2 and causes non-malignant tumors to form in different organs (primarily the brain, eyes, heart, kidney, skin and lungs) - Of TSC patients with epilepsy, 70% experience seizure onset in their first year of life - Co-morbidities include: cognitive impairment (50%), autism spectrum disorders (up to 40%), neurobehavioral disorders (over 60%) Sources: Tuberous Sclerosis Alliance; Child Neurology Foundation; Infantile Spasms Project GW Pharmaceuticals plc Investor Presentation 14
16 Commercialization
17 Commercial Manufacturing Growing & Harvesting Drying & Processing Extraction Crystallisation (API) Drug Product Manufacture Bottling & Labeling Non-GMP GMP GW has operated under commercial Good Manufacturing Practices (GMP) licenses issued outside the US since 2005 Manufacturing scaled through in-house and 3 rd party facilities Further increases in scale anticipated in 2018 and beyond to meet anticipated global demand Regulatory evaluation same as small molecule, not botanical FDA pre-approval inspections completed with no form 483 citations GW Pharmaceuticals plc Investor Presentation 16
18 Epidiolex Commercial Exclusivity Orphan Designation 7 years in the US plus expected 6-month pediatric extension 10 years in the EU plus expected 2 years pediatric extension Intellectual Property Pursuing a patent strategy designed to have patents issued to protect lead drug candidate and other pipeline candidates beyond Orphan Designation Current portfolio includes multiple distinct patent families in the treatment of epilepsy and formulations To date, 8 patents granted by the USPTO (expiry to 2035) A number of these patents expected to be listed in the Orange Book Additional patent applications expected as new data is generated Life-cycle management through new indications, formulation improvements, combinations and additional commercial geographies Proposed new formulations include liquid, solid dose, intravenous Orphan Exclusivity Patent Protections Life-Cycle Management GW Pharmaceuticals plc Investor Presentation 17
19 Epidiolex Patent Portfolio (applications in public domain numerous patents filed and not yet available through USPTO website) Patent Primary Claim Status US 9,066,920 A method of treating partial seizure comprising administering CBD at a daily dose of at least 400mg. Granted US 9,522,123 A method of treating complex partial seizure comprising administering CBD at a daily dose of at least 400mg. Granted US 9,474,726 A method of treating febrile infection related epilepsy syndrome (FIRES) comprising administering CBD) to a subject. Granted US 9,956,184 A method of reducing seizure frequency in LGS with concomitant CBD and clobazam, wherein the CBD dose is 10 mg/kg/day or greater and the purity of the CBD is greater than 98%. US 9,949,937 US 9,956,183 US 9,956,186 US 9,956,185 US 15/449,402 US 15/449,535 A method of reducing seizure frequency in Dravet syndrome with concomitant CBD and clobazam, wherein the CBD dose is 10 mg/kg/day or greater and the purity of CBD is greater than 98%. A method of reducing seizure frequency in LGS or Dravet syndrome with concomitant CBD and clobazam, wherein the dose of clobazam is reduced and the purity of CBD is greater than 98%. A method of reducing convulsive seizures in LGS with CBD, wherein the CBD dose is 10 mg/kg/day or greater and the purity of CBD is greater than 98%. A method of reducing convulsive seizures in Dravet syndrome with CBD, wherein the CBD dose is 10 mg/kg/day or greater and the purity of CBD is greater than 98%. A method of reducing drop seizure frequency in treatment-resistant childhood-onset epilepsy with CBD, wherein the CBD dose is between 5-35 mg/kg/day and the purity of CBD is greater than 98%. A method of reducing drop seizure frequency in a patient with Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC); and wherein the dose of the CBD is about 20 mg/kg/day Granted Granted Granted Granted Granted Pending Pending GW Pharmaceuticals plc Investor Presentation 18
20 Epidiolex Rescheduling FDA approval necessitates that Epidiolex be moved out of Schedule I once it has an accepted medical use Effect on Subjective Pharmacodynamic Measures (1) At the time of NDA approval, FDA recommend the appropriate lower schedule based on the abuse liability data submitted as part of the NDA Following NDA approval, DEA has up to 90 days to issue an interim final rule (IFR) to reschedule, after which Epidiolex can be marketed and dispensed GW is aiming for Epidiolex to be placed into Schedule IV - MARINOL (synthetic THC in sesame oil) Schedule III (1) Assessment of the Abuse Potential of Cannabidiol in Recreational Polydrug Users: A Randomized, Double- Blind, Controlled Trial, Sommerville et al, 2017, Greenwich Biosciences, Inc. GW Pharmaceuticals plc Investor Presentation 19
21 Epidiolex Commercialization Status Global commercialization rights to Epidiolex fully-owned by GW Pharmaceuticals Group companies In the US we will use our subsidiary, Greenwich Biosciences Inc., to commercialize our products U.S. Launch Preparations - U.S. sales organization fully recruited comprising two national directors, eight regional managers plus 66 Neurology Account Managers - Active engagement with U.S. payors ongoing with clinical presentations to plans that cover over 80% of covered lives in the U.S. - U.S. supply chain platform in place which will employ a closed model distribution network of five Specialty Pharmacy Providers (SPP s) U.S. Launch expected Fall 2018 EU commercial footprint now in place in five major European markets in readiness for 2019 European launches GW Pharmaceuticals plc Investor Presentation 20
22 Additional Programs, Financial Information and Upcoming Milestones
23 GW s Cannabinoid Platform: A Proprietary Growth Engine Beyond Epidiolex Cannabis plant is a unique source of >100 cannabinoid molecules capable of targeting diseases across therapeutic areas and mechanisms - TRP channels, adenosine re-uptake, serotonin receptors, endocannabinoid system GW has a deep pipeline of additional cannabinoid product candidates Focus on orphan pediatric neurologic conditions within epilepsy, autism, NHIE, schizophrenia Existing physician relationships through Epidiolex program U.S. development and commercialization rights to Sativex fully owned by GW, plans underway to determine MS spasticity FDA regulatory pathway GW Pharmaceuticals plc Investor Presentation 22
24 Sativex - New U.S. Late Stage Pipeline Product Oromucosal spray of a formulated extract of cannabis that contains the principal cannabinoids delta-9- tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio Approved in >25 countries outside the United States for the treatment of spasticity due to Multiple Sclerosis (MS). Product is sold via marketing partners New placebo-controlled trial data presented at ECTRIMS 2017 positive primary and secondary endpoints GW reacquired full rights to develop and commercialize Sativex in U.S. (December 2017). Previous license agreement with Otsuka terminated Represents a new wholly-owned late-stage U.S. asset We expect to evaluate the optimal route to achieve a NDA GW Pharmaceuticals plc Investor Presentation 23
25 CBDV Program CBDV in Autism Spectrum Disorders - Pre-clinical research shows promising signals on cognitive/social endpoints as well as repetitive behavior - A physician-led, FDA authorized, expanded access IND to treat seizures associated with autism in 10 patients underway - An investigator-led 100 patient placebo-controlled trial in autism is also due to commence in Q Rett syndrome - Orphan Drug Designation from FDA for CBDV for the treatment of Rett syndrome - Open-label study in Rett Syndrome expected to commence in Q Phase 2 placebo-controlled trial expected to commence Q CBDV in epilepsy (GWP42006) - CBDV looks to be differentiated from CBD in four key ways: efficacy profile in seizure models, metabolic profile, pharmacological profile and has different physico-chemical characteristics - CBDV has shown anti-epileptic properties across a range of in vitro and in vivo animal models of epilepsy - Phase 2a placebo-controlled trial (n=162) in adult patients with partial-onset epilepsy failed to differentiate from placebo on the primary endpoint as both arms showed reductions in focal seizures of approximately 40% - CBDV was generally well-tolerated with the majority of CBDV patients experiencing adverse events of mild or moderate severity - GW will continue to explore potential development opportunities for CBDV in the field of epilepsy GW Pharmaceuticals plc Investor Presentation 24
26 Recurrent Glioblastoma Multiforme (GBM) Program THC:CBD investigational product candidate for the treatment of GBM - Orphan Drug Designation from FDA GBM is the most common and most aggressive type of malignant primary brain tumor 1,2 - Typically patients succumb to the disease approximately 15 months after diagnosis - Treatment for GBM remains challenging and additional safe and effective long-term treatment options are needed - Standard treatment is surgical resection, radiotherapy and concomitant adjunctive chemotherapy Phase 2 study completed - THC:CBD + TMZ had an 83% one year survival rate compared with 44% for patients on placebo (TMZ only) (p=0.042) - Median survival for the THC:CBD group was over 662 days compared with 369 days in the placebo group 3 - THC:CBD was generally well tolerated with treatment emergent adverse events leading to discontinuation in two patients in each group - The most common adverse events (three patients or more and greater than placebo) were vomiting (75%), dizziness (67%) nausea (58%), headache (33%), and constipation (33%) 1. National Brain Tumor Society web site. "Tumor Types." 2. American Brain Tumor Association. (2012) "Glioblastoma and Malignant Astrocytoma." 3. Data reported by GW Pharmaceuticals press release 7 February 2017 GW Pharmaceuticals plc Investor Presentation 25
27 Key Financial Data Clean up ICON Cash at 30 June 2018 H cash outflow guidance ($10-$20m Capex for manufacturing expansion $440.2m $120m $140m Share Capital Current Options Fully Diluted ADS/m GW Pharmaceuticals plc Investor Presentation 26
28 Upcoming Milestones/Newsflow Expected Timing EPIDIOLEX REGULATORY DEA rescheduling Q U.S. launch Fall 2018 EMA decision Q EPIDIOLEX DATA Phase 3 tuberous sclerosis complex trial data H nd Phase 3 Dravet syndrome trial data Q EPIDIOLEX EXCLUSIVITY Track One patent decisions Ongoing PIPELINE Epidiolex in Rett syndrome IND Q CBDV investigator-led placebo control trial in autism start Q CBDV open label in Rett syndrome trial start Q FDA meeting to determine Sativex NDA requirements H CBDV Phase 2 Rett syndrome trial start Q GW Pharmaceuticals plc Investor Presentation 27
29 Thank You GW Pharmaceuticals plc NASDAQ: GWPH Stephen Schultz, VP Investor Relations
Investor Presentation
Investor Presentation 2018 GW Pharmaceuticals plc All Rights Reserved Disclaimers FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management s beliefs
More informationNASDAQ: GWPH March, 2019
NASDAQ: GWPH March, 2019 Grace Living with Dravet syndrome, Being treated with Epidiolex 2019 GW Pharmaceuticals. All rights reserved. Forward-Looking Statements This presentation contains forward-looking
More informationGW Pharmaceuticals plc. Investor Presentation August 2014
GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations
More informationGW Pharmaceuticals plc. Investor Presentation May 2015
GW Pharmaceuticals plc Investor Presentation May 2015 Disclaimers FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management s beliefs and assumptions
More informationGW Pharmaceuticals plc. June 2016
GW Pharmaceuticals plc June 2016 Disclaimers FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are based on our management s beliefs and assumptions and on information
More informationGW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
December 7, 2015 GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy As previously announced, seven posters
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationForm 6-K. GW PHARMACEUTICALS PLC (Translation of registrant s name into English)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month
More informationGW Pharmaceuticals plc Reports Third Quarter 2015 Financial Results and Operational Progress
August 6, 2015 GW Pharmaceuticals plc Reports Third Quarter 2015 Financial Results and Operational Progress - Four Phase 3 epilepsy clinical trials underway - First Phase 3 trial fully enrolled - - U.S.
More informationCannabinoids and Epilepsy. Michael Ciliberto, MD University of Iowa Stead Family Department of Pediatrics
Cannabinoids and Epilepsy Michael Ciliberto, MD University of Iowa Stead Family Department of Pediatrics Cannabinoids Cannabinoids= terpenophenolic compounds (give a scent) >80 in Cannabis sativa Cannabidiol
More informationCannabis in the treatment of Autism:
Cannabis in the treatment of Autism: Are we ready? Deb Karhson, PhD and Lawrence Fung, MD, PhD Cannabis Anecdotal Data: Comparing Epilepsy and Autism+ Science of Cannabinoids: Endocannabinoid System Receptor
More informationSubject: Cannabidiol (Epidiolex )
09-J3000-08 Original Effective Date: 09/15/18 Reviewed: 08/08/18 Revised: 00/00/00 Next Review: 04/10/19 Subject: Cannabidiol (Epidiolex ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationNASDAQ: ZGNX Corporate Update
NASDAQ: ZGNX Corporate Update June 2016 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationAXIM Biotechnologies Reports Year End 2017 Results
March 19, 2018 AXIM Biotechnologies Reports Year End 2017 Results NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research
More informationGanaxolone as a Treatment for Drug-Resistant Epilepsy in Children
Ganaxolone as a Treatment for Drug-Resistant Epilepsy in Children ANTIEPILEPTIC DRUG and DEVICE TRIALS XIII May 13-15, 2015 Turnberry Isle Miami Hotel Gail M. Farfel, PhD Chief Development & Regulatory
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008
More informationJP Morgan. January 2019
JP Morgan January 2019 Disclaimer THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E
More informationDr. Hagit Marchaim, Regulatory Affairs & Drug Development Consulting - HMC
Dr. Hagit Marchaim, Regulatory Affairs & Drug Development Consulting - HMC 1 Disclosures I (Dr. Hagit Marchaim) have no financial relationships to disclose concerning the content of this presentation or
More informationEpidiolex (cannabidiol) NEW PRODUCT SLIDESHOW
Epidiolex (cannabidiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Epidiolex Generic name: Cannabidiol Pharmacological class: Cannabinoid Strength and Formulation: 100mg/mL; oral soln; strawberry-flavored;
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationChanging the Drug Enforcement Administration (DEA) Schedule of Tetrahydrocannabinol (THC), Cannabidiol and Combinations to Promote Research
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 TITLE: Changing the Drug Enforcement Administration (DEA) Schedule of Tetrahydrocannabinol
More information2013 H1/Q2 Financial Results AIM: GWP NASDAQ: GWPH
2013 H1/Q2 Financial Results AIM: GWP NASDAQ: GWPH June 3, 2013 Forward Looking Statements and Disclaimer This presentation contains forward looking statements. Some of the matters discussed concerning
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationUCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationMedicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer
Medicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer Medicinal cannabis Substantial public interest Legalised by the Qld Government Guidance
More informationSTUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017
STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationInvestigational Pharmacy Cannabidiol treatment in Epilepsy
Jon Beck BS Pharm D Coordinator Investigational Pharmacy Disclosure I have no relevant financial relationships with a Commercial Provider Nebraska Medicine Omaha, NE Investigational Pharmacy Cannabidiol
More informationDravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 BioPortfolio has been marketing business
More informationBudding Therapies: Medical Cannabis and its Uses
Budding Therapies: Medical Cannabis and its Uses MARIAH CADAVOS, PHARMD & VIVIAN NGUYEN, PHARMD PGY1 PHARMACY PRACTICE RESIDENTS FEBRUARY 10, 2019 1 Disclosures & Disclaimer Both presenters have nothing
More informationMedicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system
Medicinal cannabis What is medicinal cannabis? Broadly speaking, medicinal cannabis is cannabis prescribed to relieve the symptoms of a medical condition, such as epilepsy. It is important to make the
More informationCompany Update with a Focus on Pipeline
NASDAQ: Company Update with a Focus on Pipeline December 2014 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts
More informationFederal Law: Marijuana
Federal Law: Marijuana Marijuana is a Schedule I drug under Federal Controlled Substances Act Makes possession, usage, purchase, sale, and/or cultivation of marijuana illegal at the federal level May not
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationThe Shifting Federal Regulation of Cannabis Products
The Durham Bar 2019 CLE Program The Shifting Federal Regulation of Cannabis Products Erica M. Jackson, FDA Partner K&L Gates February 6, 2019 Copyright 2018 by K&L Gates LLP. All rights reserved. OVERVIEW
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationCreating a Leading Global HBV Therapeutics Company. ARB-1467 Update Call December 12, 2016
Creating a Leading Global HBV Therapeutics Company ARB-1467 Update Call December 12, 2016 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationThe products being taken by children with epilepsy are not the equivalent of the marijuana widely used for recreational purposes.
Epilepsy Foundation of Colorado The Use of Cannabis to Treat Children with Epilepsy Updated February 2016 The use of extracts from marijuana plants (cannabis) to treat children with epilepsy has been in
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationEpidiolex in Dravet Syndrome and Lennox- Gestaut Syndrome (LGS) 27 September 2018 Presented by: Giuliana Campo 2019 PharmD Candidate 1
Epidiolex in Dravet Syndrome and Lennox- Gestaut Syndrome (LGS) 27 September 2018 Presented by: Giuliana Campo 2019 PharmD Candidate 1 Objectives To understand the epidemiology and pathophysiology of LGS
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationGeorgia Cannabidiol Study Frequently Asked Questions
Georgia Cannabidiol Study Frequently Asked Questions 1. Why was the Georgia Cannabidiol Study initiated? In January 2014, Representative Allen Peake visited with Haleigh Cox, a 4-year-old girl with severe
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationRespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit
RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,
More informationNASDAQ: Company Update. January 2015
NASDAQ: Company Update January 2015 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements.
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationDavid Zaccardelli, PharmD Chief Executive Officer. J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019
David Zaccardelli, PharmD Chief Executive Officer J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019 Disclaimer Certain information contained in this presentation relates to or is based on
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationCANNABIDIOL (CBD) THE BE ALL END ALL?
CANNABIDIOL (CBD) THE BE ALL END ALL? John Schaeffer, DO PMG neurology specialists Clinical associate professor Department of neurology University of Washington school of medicine CANNABIS BRIEF HISTORY
More informationZynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome - Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationCommercial-Stage Bioelectronic Medicine Company 1 st FDA-cleared non-invasive vagus nerve stimulation platform therapy
Commercial-Stage Bioelectronic Medicine Company 1 st FDA-cleared non-invasive vagus nerve stimulation platform therapy 2018 electrocore. All rights reserved. 1 Disclaimer This presentation may contain
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCannabis for Drug Resistant Epilepsy
Cannabis for Drug Resistant Epilepsy MILA SORIN, MD PEDIATRIC NEUROLOGY APRIL 20, 2018 Introduction -Although more than 20 prescription anti-epileptic drugs (AEDs) are available, they prove to be ineffective
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationMedical Marijuana. Navigating Medical Marijuana in Workers Compensation
Medical Marijuana Navigating Medical Marijuana in Workers Compensation Agenda Federal and State Laws Public Health Adverse Effects & Concerns Clinical Use Implications for Employers Implications for Workers
More informationLauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST
Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Forward Looking Statements Certain statements contained
More informationCompany Overview. Dr. Neal Walker President and CEO. September Copyright 2016 Aclaris Therapeutics. All rights reserved.
Company Overview Dr. Neal Walker President and CEO Copyright 2016 Aclaris Therapeutics. All rights reserved. A-11 Disclaimer This presentation contains forward-looking statements, including statements
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationCannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults
NIHR Innovation Observatory Evidence Briefing: June 2017 Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults NIHRIO (HSRIC) ID: 11079
More informationNovel Medicines for Life-Altering CNS Disorders
Novel Medicines for Life-Altering CNS Disorders November 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forwardlooking statements, which may be identified by
More information2 nd Line Treatments for Dravet. Eric BJ Ségal, MD Northeast Regional Epilepsy Group
2 nd Line Treatments for Dravet Eric BJ Ségal, MD Northeast Regional Epilepsy Group Disclosures Accepted honoraria from Greenwich Pharmaceuticals, Zogenix, Eisai, Lundbeck, Lineagen. Overview Evidence
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationPostpartum depression is the most common medical complication of childbirth, estimated to affect approximately 400,000 women annually in the U.S.
Sage Therapeutics Announces FDA Approval of ZULRESSO (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression March 19, 2019 Approval based on results from
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationMedical Cannabis MATT WEBSTER DO, MS
Medical Cannabis MATT WEBSTER DO, MS Cannabis Sativa One of the oldest used drugs and medicinal remedies Most commonly abused illicit drug in the US There has been increasing access for medicinal MJ use
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationDear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE
Directorate of Chief Medical Officer T: 0131-244 2470 E: John.Hannah@gov.scot Dear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE Following my letter of 31 October 2018
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationQuality Assessments for an Organically-Complex Drug - Part 1 Background and the Chemometrics Role
Quality Assessments for an Organically-Complex Drug - Part 1 Background and the Chemometrics Role Dr Peter Gibson Technical Director Sovereign House, Vision Park, Histon, Cambridge, CB24 9BZ Global leaders
More informationStrengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018
Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements
More informationLundbeck reports positive phase III study results for clobazam in the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome
H. Lundbeck A/S Ottiliavej 9 Tel +45 36 30 13 11 E-mail investor@lundbeck.com DK-2500 Valby, Copenhagen Fax +45 36 43 82 62 www.lundbeck.com CVR number: 56759913 Corporate Release No 419 4 December 2010
More informationFebruary 20, 2019 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES
February 20, 209 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES Forward-Looking Statements This presentation contains certain forward-looking statements that are made pursuant
More information